Effect of Betahistine and Metformin on Antipsychotic-Induced Weight Gain: An Analysis of Two Clinical Trials

Dongyu Kang, Zhihui Jing, Ranran Li, Gangrui Hei, Tiannan Shao, Li Li, Mengxi Sun, Ye Yang, Ying Wang, Xiaoyi Wang, Yujun Long, Xiansheng Huang, Renrong Wu, Dongyu Kang, Zhihui Jing, Ranran Li, Gangrui Hei, Tiannan Shao, Li Li, Mengxi Sun, Ye Yang, Ying Wang, Xiaoyi Wang, Yujun Long, Xiansheng Huang, Renrong Wu

Abstract

Antipsychotic-induced weight gain is one of the most common adverse effects of antipsychotic treatment. However, there are no well-established interventions for the weight gain yet. In this study, we pooled the data from two clinical trials, which were originally examining the efficacy of betahistine and the efficacy of metformin in treating antipsychotic-induced weight gain and insulin resistance. A total of 67 people with schizophrenia or bipolar disorder treated with antipsychotics were assigned to 36 mg day-1 betahistine (n = 13) or 1,000 mg day-1 metformin (n = 25) or placebo (n = 29) treatment for 12 weeks, with evaluation at baseline and week 12. The primary outcome was the body mass index (BMI). After treatment, metformin group had a mean decrease in BMI of 1.46 ± 0.14 (p < 0.001) and insulin resistance index (IRI) of 4.30 ± 2.02 (p < 0.001). The betahistine group had no significant alteration in BMI or IRI. However, placebo group had a mean increase in BMI of 1.27 ± 0.77 (p < 0.001) and IRI of 0.45 ± 0.86 (p < 0.001). Between the two treatment groups, metformin significantly decreased weight, BMI, fasting glucose, insulin level, and IRI but not waist circumference when compared with betahistine. Moreover, metformin significantly decreased weight, BMI, waist circumference, fasting glucose, insulin level, and IRI when compared with placebo, whereas betahistine significantly decreased body weight, waist circumference, BMI, insulin level, and IRI but not fasting glucose when compared with placebo. In this study, we found that both metformin treatment and betahistine treatment were efficacious in improving antipsychotic-induced weight gain and insulin resistance, and metformin was more efficacious in preventing and revising the weight gain induced by antipsychotics. Clinical Trial Registration: www.ClinicalTrials.gov, NCT00451399(Study 1), NCT00709202(Study 2).

Keywords: BMI; antipsychotic medication; betahistine; insulin resistance; metformin.

References

    1. Hirsch L, Yang J, Bresee L, Jette N, Patten S, Pringsheim T. Second-generation antipsychotics and metabolic side effects: a systematic review of population-based studies. Drug Saf. (2017) 40:771–81. 10.1007/s40264-017-0543-0
    1. Bak M, Fransen A, Janssen J, Van Os J, Drukker M. Almost all antipsychotics result in weight gain: a meta-analysis. PLoS One (2014) 9:e94112. 10.1371/journal.pone.0094112
    1. Rummel-Kluge C, Komossa K, Schwarz S, Hunger H, Schmid F, Lobos CA, et al. . Head-to-head comparisons of metabolic side effects of second generation antipsychotics in the treatment of schizophrenia: a systematic review and meta-analysis. Schizophr Res. (2010) 123:225–33. 10.1016/j.schres.2010.07.012
    1. Correll CU, Joffe BI, Rosen LM, Sullivan TB, Joffe RT. Cardiovascular and cerebrovascular risk factors and events associated with second-generation antipsychotic compared to antidepressant use in a non-elderly adult sample: results from a claims-based inception cohort study. World Psychiatry (2015) 14:56–63. 10.1002/wps.20187
    1. Weiden PJ, Mackell JA, McDonnell DD. Obesity as a risk factor for antipsychotic noncompliance. Schizophr Res. (2004) 66:51–7. 10.1016/S0920-9964(02)00498-X
    1. Mitchell AJ, Vancampfort D, De Herdt A, Yu W, De Hert M. Is the prevalence of metabolic syndrome and metabolic abnormalities increased in early schizophrenia? A comparative meta-analysis of first episode, untreated and treated patients. Schizophr Bull. (2013) 39:295–305. 10.1093/schbul/sbs082
    1. Alvarez-Jiménez M, González-Blanch C, Vázquez-Barquero JL, Pérez-Iglesias R, Martínez-García O, Pérez-Pardal T, et al. . Attenuation of antipsychotic-induced weight gain with early behavioral intervention in drug-naive first-episode psychosis patients: a randomized controlled trial. J Clin Psychiatry (2006) 67:1253–60. 10.4088/JCP.v67n0812
    1. Bartoli F, Carrà G, Crocamo C, Carretta D, Clerici M. Bipolar disorder, schizophrenia, and metabolic syndrome. Am J Psychiatry (2013) 170:927–8. 10.1176/appi.ajp.2013.13040447
    1. Clerici M, Bartoli F, Carretta D, Crocamo C, Bebbington P, Carrà G. Cardiovascular risk factors among people with severe mental illness in Italy: a cross-sectional comparative study. Gen Hosp Psychiatry (2014) 36:698–702. 10.1016/j.genhosppsych.2014.08.005
    1. De Hert M, Schreurs V, Van Vancampfort D, Winkel R. Metabolic syndrome in people with schizophrenia: a review. World Psychiatry (2009) 8:15–22. 10.1172/JCI13505
    1. Zhou G, Myers R, Li Y, Chen Y, Shen X, Fenyk-Melody J, et al. . Role of AMP-activated protein kinase in mechanism of metformin action. J Clin Invest. (2001) 108:1167–74. 10.1172/JCI200113505
    1. Wu R-R, Zhao J, Jin H, Shao P, Fang M-S, Guo X, et al. . Lifestyle intervention and metformin for treatment of antipsychotic-induced weight gain. JAMA (2008) 299:185–93. 10.1001/jama.2007.56-b
    1. Wu R.-R., Zhang F.-Y., Gao K.-M., Ou J.-J., Shao P., Jin H., et al. . Metformin treatment of antipsychotic-induced dyslipidemia: an analysis of two randomized, placebo-controlled trials (2016). Mol. Psychiatry 21:1537–44. 10.1038/mp.2015.221
    1. Wu RR, Jin H, Gao K, Twamley EW, Ou JJ, Shao P, et al. . Metformin for treatment of antipsychotic-induced amenorrhea and weight gain in women with first-episode schizophrenia: a double-blind, randomized, placebo-controlled study. Am J Psychiatry (2012) 169:813–21. 10.1176/appi.ajp.2012.11091432
    1. Wu RR, Zhao JP, Guo XF, He YQ, Fang MS, Guo W, et al. . Metformin addition attenuates olanzapine-induced weight gain in drug-naive first-episode schizophrenia patients: A double-blind, placebo-controlled study. Am. J. Psychiatry (2008) 165:352–8. 10.1176/appi.ajp.2007.07010079
    1. Lee A, Morley JE. Metformin decreases food consumption and induces weight loss in subjects with obesity with type II non-insulin-dependent diabetes. Obes Res. (1998) 6:47–53. 10.1002/j.1550-8528.1998.tb00314.x
    1. Malin SK, Kashyap SR. Effects of metformin on weight loss: potential mechanisms. Curr Opin Endocrinol Diabetes Obes. (2014) 21:323–9. 10.1097/MED.0000000000000095
    1. Deng C, Weston-Green K, Huang XF. The role of histaminergic H1 and H3 receptors in food intake: a mechanism for atypical antipsychotic-induced weight gain? Prog Neuro Psychopharmacology Biol Psychiatry (2010) 34:1–4. 10.1016/j.pnpbp.2009.11.009
    1. Deng C, Lian J, Pai N, Huang X-F. Reducing olanzapine-induced weight gain side effect by using betahistine: a study in the rat model. J Psychopharmacol. (2012) 26:1271–9. 10.1177/0269881112449396
    1. Lian J, Huang XF, Pai N, Deng C. Preventing olanzapine-induced weight gain using betahistine: a study in a rat model with chronic olanzapine treatment. PLoS ONE (2014) 9:e104160. 10.1371/journal.pone.0104160
    1. Barak N, Beck Y, Albeck JH. Betahistine decreases olanzapine-induced weight gain and somnolence in humans. J Psychopharmacol. (2016) 30:237–41. 10.1177/0269881115626349
    1. Barak N, Beck Y. Betahistine safely mitigates olanzapine induced weight gain and sleepiness. Int J Neuropsychopharmacol. (2010) 13:87.
    1. American Psychiatric Association Diagnostic and Statistical Manual of Mental Disorders: DSM-IV. Washington, DC: American Psychiatric Association; (1994).
    1. First MB, Spitzer RL, Gibbon M, Williams JBW. Structured Clinical Interview for DSM-IV-TR Axis I Disorders, Research Version, Non-patient Edition, for DSMIV (2002).
    1. Haffner SM, Miettinen H, Stern MP. The homeostasis model in the San Antonio Heart Study. Diabetes Care (1997) 20:1087–92. 10.2337/diacare.20.7.1087
    1. Dayabandara M, Hanwella R, Ratnatunga S, Seneviratne S, Suraweera C, de Silva VA. Antipsychotic-associated weight gain: Management strategies and impact on treatment adherence. Neuropsychiatr. Dis. Treat. (2017) 13:2231–41. 10.2147/NDT.S113099
    1. Essock SM, Covell NH, Davis SM, Stroup TS, Rosenheck RA, Lieberman JA. Effectiveness of switching antipsychotic medications. Am J Psychiatry (2006) 163:2090–5. 10.1176/ajp.2006.163.12.2090
    1. Weiden PJ. Switching antipsychotic medications: Not enough, too often, or just right? Am J Psychiatry (2011) 168:882–4. 10.1176/appi.ajp.2011.11060958
    1. Álvarez-Jiménez M, Hetrick SE, González-Blanch C, Gleeson JF, McGorry PD. Non-pharmacological management of antipsychotic-induced weight gain: Systematic review and meta-analysis of randomised controlled trials. Br J Psychiatry (2008) 193:101–7. 10.1192/bjp.bp.107.042853
    1. Park S, Harrold JA, Widdowson PS, Williams G. Increased binding at 5-HT(1A), 5-HT(1B), and 5-HT(2A) receptors and 5-HT transporters in diet-induced obese rats. Brain Res. (1999) 847:90–7. 10.1016/S0006-8993(99)02055-7
    1. Sethi J, Sanchez-Alavez M, Tabarean IV. Loss of histaminergic modulation of thermoregulation and energy homeostasis in obese mice. Neuroscience (2012) 217:84–95. 10.1016/j.neuroscience.2012.04.068
    1. He M, Deng C, Huang XF. The role of hypothalamic H1 receptor antagonism in antipsychotic-induced weight gain. CNS Drugs (2013) 27:423–34. 10.1007/s40263-013-0062-1
    1. Kroeze WK, Hufeisen SJ, Popadak BA, Renock SM, Steinberg S, Ernsberger P, et al. . H1-Histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs. Neuropsychopharmacology (2003) 28:519–26. 10.1038/sj.npp.1300027
    1. Barak N. Betahistine: what's new on the agenda? Expert Opin Investig Drugs (2008) 17:795–804. 10.1517/13543784.17.5.795
    1. Barak N, Greenway FL, Fujioka K, Aronne LJ, Kushner RF. Effect of histaminergic manipulation on weight in obese adults: a randomized placebo controlled trial. Int J Obes. (2008) 32:1559–65. 10.1038/ijo.2008.135
    1. Poyurovsky M, Pashinian A, Levi A, Weizman R, Weizman A. The effect of betahistine, a histamine H1 receptor agonist/H3 antagonist, on olanzapine-induced weight gain in first-episode schizophrenia patients. Int Clin Psychopharmacol. (2005) 20:101–3.
    1. Poyurovsky M, Fuchs C, Pashinian A, Levi A, Weizman R, Weizman A. Reducing antipsychotic-induced weight gain in schizophrenia: a double-blind placebo-controlled study of reboxetine-betahistine combination. Psychopharmacology (2013) 226:615–22. 10.1007/s00213-012-2935-2
    1. Poyurovsky M, Fuchs C, Pashinian A, Levi A, Faragian S, Maayan R, et al. . Attenuating effect of reboxetine on appetite and weight gain in olanzapine-treated schizophrenia patients: a double-blind placebo-controlled study. Psychopharmacology (2007) 192:441–8. 10.1007/s00213-007-0731-1
    1. Al-Anbari HH, Al-Zubaidy AA, Khazaal FA. Effect of Betahistine and Metformin on Lipid Profile in Obese Females in Iraq: a Randomized, Placebo-Controlled Clinical Trial. Iraqi J Med Sci. (2016) 14:320–9. 10.22578/IJMS.14.4.5
    1. Ali AH, Yanoff LB, Stern EA, Akomeah A, Courville A, Kozlosky M, et al. Acute effects of betahistine hydrochloride on food intake and appetite in obese women: a randomized, placebo-controlled trial 30. Am J Clin Nutr (2010) 92:1290–7. 10.3945/ajcn.110.001586
    1. Hostalek U, Gwilt M, Hildemann S. Therapeutic use of metformin in prediabetes and diabetes prevention. Drugs (2015) 75:1071–94. 10.1007/s40265-015-0416-8
    1. IDF Clinical Guidelines Task Force Global Guideline for Type 2 Diabetes: recommendations for standard, comprehensive, and minimal care. Diabet Med. (2006) 23:579–93. 10.1111/j.1464-5491.2006.01918.x
    1. Lee CK, Choi YJ, Park SY, Kim JY, Won KC, Kim YW. Intracerebroventricular injection of metformin induces anorexia in rats. Diabetes Metab J. (2012) 36:293–9. 10.4093/dmj.2012.36.4.293
    1. Lv WS, Wen JP, Li L, Sun RX, Wang J, Xian YX, et al. . The effect of metformin on food intake and its potential role in hypothalamic regulation in obese diabetic rats. Brain Res. (2012) 1444:11–9. 10.1016/j.brainres.2012.01.028
    1. Aubert G, Mansuy V, Voirol MJ, Pellerin L, Pralong FP. The anorexigenic effects of metformin involve increases in hypothalamic leptin receptor expression. Metabolism. (2011) 60:327–34. 10.1016/j.metabol.2010.02.007
    1. Poleni PE, Akieda-Asai S, Koda S, Sakurai M, Bae CR, Senba K, et al. . Possible involvement of melanocortin-4-receptor and AMP-activated protein kinase in the interaction of glucagon-like peptide-1 and leptin on feeding in rats. Biochem Biophys Res Commun. (2012) 420:36–41. 10.1016/j.bbrc.2012.02.109
    1. Li R, Zhao J, Wu R. Predictors of menstruation restoration during metformin administration for treatment of antipsychotic drug-induced amenorrhea: a post-hoc analysis. Schizophr Res. (2016) 190:121–2. 10.1016/j.schres.2017.03.019
    1. Zheng W, Zhang Q-E, Cai D-B, Yang X-H, Ungvari G, Ng C, et al. . Combination of metformin and lifestyle intervention for antipsychotic-related weight gain: a meta-analysis of randomized controlled trials. Pharmacopsychiatry (2018) 51: e1–8. 10.1055/s-0044-101466
    1. de Silva VA, Suraweera C, Ratnatunga SS, Dayabandara M, Wanniarachchi N, Hanwella R. Metformin in prevention and treatment of antipsychotic induced weight gain: a systematic review and meta-analysis. BMC Psychiatry (2016) 16:341. 10.1186/s12888-016-1049-5
    1. de Silva VA, Dayabandara M, Wijesundara H, Henegama T, Gunewardena H, Suraweera C, et al. Metformin for treatment of antipsychotic-induced weight gain in a South Asian population with schizophrenia or schizoaffective disorder: a double blind, randomized, placebo controlled study. J Psychopharmacol. (2015) 29:1255–61. 10.1177/0269881115613519
    1. Zheng W, Li X-B, Tang Y-L, Xiang Y-Q, Wang C-Y, de Leon J. Metformin for Weight Gain and Metabolic Abnormalities Associated With Antipsychotic Treatment. J Clin Psychopharmacol. (2015) 35:499–509. 10.1097/JCP.0000000000000392
    1. Bartoli F, Lax A, Crocamo C, Clerici M, Carrà G. Plasma adiponectin levels in schizophrenia and role of second-generation antipsychotics: a meta-analysis. Psychoneuroendocrinology (2015) 56:179–89. 10.1016/j.psyneuen.2015.03.012
    1. Bartoli F, Crocamo C, Clerici M, Carrà G. Second-generation antipsychotics and adiponectin levels in schizophrenia: A comparative meta-analysis. Eur Neuropsychopharmacol. (2015) 25:1767–74. 10.1016/j.euroneuro.2015.06.011
    1. Potvin S, Zhornitsky S, Stip E. Antipsychotic-induced changes in blood levels of leptin in schizophrenia: a meta-analysis. Can J Psychiatry (2015) 60(3 Suppl. 2):S26–34.

Source: PubMed

Sponsorer och medarbetare

Medicinska tillstånd

Läkemedelsinterventioner

3
Prenumerera